BENEFIT OF HEPARIN IN CENTRAL VENOUS AND PULMONARY-ARTERY CATHETERS -A METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Citation
Ag. Randolph et al., BENEFIT OF HEPARIN IN CENTRAL VENOUS AND PULMONARY-ARTERY CATHETERS -A METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS, Chest, 113(1), 1998, pp. 165-171
Citations number
32
Categorie Soggetti
Respiratory System","Cardiac & Cardiovascular System
Journal title
ChestACNP
ISSN journal
00123692
Volume
113
Issue
1
Year of publication
1998
Pages
165 - 171
Database
ISI
SICI code
0012-3692(1998)113:1<165:BOHICV>2.0.ZU;2-L
Abstract
Objective: To evaluate the effect of heparin on thrombus formation and infection associated with use of central venous and pulmonary artery catheters. Data sources: We used MEDLINE, EMBASE, citation review of r elevant primary and review articles, personal files, and contact with expert informants, Study selection: Fourteen randomized controlled tri als evaluating prophylactic doses of heparin or heparin bonding were i ncluded. Data extraction: In duplicate, independently, we abstracted d ata on the population, intervention, outcome, and methodologic quality . Data synthesis: Prophylactic heparin decreases catheter-related veno us thrombosis (relative risk [RR], 0.43; 95% confidence interval [CI], 0.23, 0.78) and bacterial colonization (RR, 0.18; 95% CI, 0.06, 0.60) of central venous catheters and may decrease catheter-related bactere mia (RR, 0.26; 95% CI, 0.07, 1.03). Heparin bonding decreases the risk of pulmonary artery catheter clot formation within 24 h (RR, 0.08; 95 % CI, 0.02, 0.37). Conclusions: Heparin administration effectively red uces thrombus formation and may reduce catheter-related infections in patients who have central venous and pulmonary artery catheters in pla ce. Cost-effectiveness comparisons of unfractionated heparin, low mole cular weight heparin, and warfarin are needed.